ZILBRYSQ
Live / Registered — Registered (as of 28 Jan 2025)
What this means for you
Registered since 28 Jan 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98179729
- Registration number
- 7673264
- Mark type
- Stylized text
- Filed
- 14 Sept 2023
- Published for opposition
- 18 Jun 2024
- Registered
- 28 Jan 2025
- Attorney of record
- Kumiko Ide
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, for human use, for the prevention and treatment of myasthenia gravis
- Class 010 — Medical apparatus: Syringes for injections; Syringes for medical purposes; Syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication
Owner
- UCB HOLDINGS, INC., SMYRNA, GA, US
- Ra Pharmaceuticals, Inc., Cambridge, MA, US
- Ra Pharmaceuticals, Inc., Cambridge, MA, US
- Ra Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 24 Feb 2025 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 28 Jan 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 28 Jan 2025 — REGISTERED-PRINCIPAL REGISTER
- 06 Jan 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 06 Jan 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 26 Nov 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Nov 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 25 Nov 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 14 Nov 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 14 Nov 2024 — NON-FINAL ACTION E-MAILED
- 14 Nov 2024 — SU - NON-FINAL ACTION - WRITTEN
- 29 Oct 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 27 Aug 2024 — USE AMENDMENT FILED
- 29 Oct 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 27 Aug 2024 — TEAS STATEMENT OF USE RECEIVED